Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A.

Dig Dis Sci. 2011 Aug;56(8):2439-48. doi: 10.1007/s10620-011-1746-3.

PMID:
21633833
2.

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.

Keeffe EB, Hollinger FB.

Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S. Review.

PMID:
9305673
3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

4.

Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.

Hartwell D, Shepherd J.

Int J Technol Assess Health Care. 2009 Jan;25(1):56-62. doi: 10.1017/S0266462309090084. Review.

PMID:
19126252
5.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
6.

Treatment of hepatitis C virus genotype 3-infection.

Pol S, Vallet-Pichard A, Corouge M.

Liver Int. 2014 Feb;34 Suppl 1:18-23. doi: 10.1111/liv.12405. Review.

PMID:
24373074
7.

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.

Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ.

Clin Infect Dis. 2013 Apr;56(7):961-7. doi: 10.1093/cid/cis1031. Review.

8.
9.

Clinical trial results of peginterferons in combination with ribavirin.

Craxi A, Licata A.

Semin Liver Dis. 2003;23 Suppl 1:35-46. Review.

PMID:
12934167
10.

Consensus guidelines for the management of hepatitis C infection.

Consensus Guidelines Committee for the Management of Hepatitis C Infection..

Saudi Med J. 2003 Jul;24 Suppl 2:S99-118.

PMID:
25121186
11.

Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.

Francesca Donato M, Banfi G, Cresseri D, Battista Fogazzi G, Martin P, Messa P, Fabrizi F.

Int J Artif Organs. 2013 May 17;36(5):367-72. doi: 10.5301/ijao.5000199. Review.

PMID:
23446762
12.

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O.

Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):212-23. doi: 10.1038/nrgastro.2011.21. Review.

PMID:
21386812
13.

Tailor-made therapy for viral hepatitis: recent advances.

Kudo M.

Digestion. 2011;84 Suppl 1:1-4. doi: 10.1159/000333207. Review.

14.

From non-A, non-B hepatitis to hepatitis C virus cure.

Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH.

J Hepatol. 2015 Apr;62(1 Suppl):S87-99. doi: 10.1016/j.jhep.2015.02.006. Review.

15.

[Which treatment options are validated for chronic viral hepatitis?].

Höner zu Siederdissen C, Manns MP, Cornberg M.

Internist (Berl). 2013 Dec;54(12):1427-8, 1430-3. doi: 10.1007/s00108-013-3319-3. Review. German.

PMID:
24258199
16.

Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder.

El-Baky NA, Uversky VN, Redwan EM.

Cytokine Growth Factor Rev. 2015 Dec;26(6):637-45. doi: 10.1016/j.cytogfr.2015.07.012. Review.

PMID:
26169931
17.

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Kiladjian JJ, Giraudier S, Cassinat B.

Leukemia. 2016 Apr;30(4):776-81. doi: 10.1038/leu.2015.326. Review.

PMID:
26601783
Items per page

Supplemental Content

Support Center